PMID: 2105824Jan 15, 1990Paper

Functional recovery after destruction of dopamine systems in the nucleus accumbens of rats. I. Behavioral and biochemical studies

Brain Research
G WolterinkJ M van Ree

Abstract

Bilateral 6-hydroxydopamine (6-OHDA) lesions in the nucleus accumbens of rats induced motor hypoactivity 7 days after the lesion. Spontaneous functional recovery of this impaired behavior occurred in 3-4 weeks. Behavioral and biochemical studies suggest that the hypoactivity is due to damage of the dopamine systems in the nucleus accumbens. The 6-OHDA lesions induced a decrease in the nucleus accumbens levels of dopamine and its metabolites of about 30% both 7 and 20 days after the lesion. The in vitro uptake of [3H]dopamine in nucleus accumbens tissue of the 6-OHDA-lesioned rats was decreased to the same extent at 7, 14 and 28 days after the lesion. Scatchard analysis of [3H]haloperidol binding studies in nucleus accumbens tissue revealed a shift from one type of binding site in tissue of sham-lesioned rats to two types of binding sites in tissue of 6-OHDA-lesioned rats 29 days after the lesion. This shift was not present in nucleus accumbens tissue 8 days after a 6-OHDA lesion. The spontaneously recovered rats showed an enhanced behavioral response upon administration of the dopamine agonist apomorphine. The present data suggest that the spontaneous functional recovery of impaired motor activity is caused by the development o...Continue Reading

References

Dec 15, 1978·Psychopharmacology·P Muller, P Seeman
Feb 1, 1979·Journal of Comparative and Physiological Psychology·J S Fink, G P Smith
Apr 1, 1985·Pharmacology, Biochemistry, and Behavior·M RobinM G Palfreyman
Jul 1, 1985·Journal of Neurochemistry·C MissaleI Hanbauer
Feb 1, 1970·Journal of Neurochemistry·N J Uretsky, L L Iversen
Jun 1, 1969·Brain Research·G Raisman
Sep 16, 1983·European Journal of Pharmacology·J M Van ReeD De Wied
Jun 10, 1981·European Journal of Pharmacology·J M Van Ree, G Wolterink

❮ Previous
Next ❯

Citations

Mar 1, 1992·Behavioral and Neural Biology·M J AttellaD G Stein
Mar 1, 1993·The European Journal of Medicine·L F Perrin, P E Laurent
Mar 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M KurachiY Sakurai
Jan 1, 1997·Life Sciences·J D AlvaroR S Duman
Nov 5, 1998·Pharmacology, Biochemistry, and Behavior·J E AbermanJ D Salamone
Oct 1, 1996·Brain Research. Brain Research Reviews·C L DarlingtonP F Smith
Nov 26, 2002·Behavioural Brain Research·Mercè CorreaJohn D Salamone
Aug 19, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ana G Gutiérrez-GarcíaMargarita Saavedra
May 2, 2001·Parkinsonism & Related Disorders·J N. JoyceT Beach
Dec 1, 1995·Journal of Neurotrauma·E ShohamiJ Weidenfeld
Mar 1, 1993·Pharmacology, Biochemistry, and Behavior·J M De BrabanderC G Van Eden
Apr 23, 2005·The European Journal of Neuroscience·Susana MingoteJohn D Salamone
Dec 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·P E VosJ M van Ree

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here